Immunonutrition in clinical practice

Steven Darryll Heys, Andrew Craig Schofield, Klaus Wilfried Juergen Wahle

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The clinical trials of immunonutrition that we have undertaken have often been small, single centre studies. They have often been of limited statistical power and have often included patients with a variety of underlying disease states and at different points in the disease process. Three meta-analysis and a consensus statement in conjunction with a systematic review, have been performed in an attempt to overcome many of these limitations and understand further the clinical place for immunonutrition. However, there are still many questions regarding the place of immunonutrition in clinical practice that we still do not understand or have definitive answers to. For example, do we really know what is the optimal combination of nutrients and in what quantities they should be provided? Do we understand any potential interactions that might occur between these nutrients? What is the effect of the patients nutritional state? When and for how long should immunonutrition provided? What is the impact of the patients' underlying disease process and how does this interact with the provision of immunonutrition? At the present time whilst there is some indication and evidence as to which patients might benefit most, and as to those who may not benefit or even suffer detrimental effects from immunonutrition, we still can not answer these questions with any definitive authority. It is essential now that we undertake large well designed, well controlled multicentre studies with adequate statistical power to answer these questions. The indications are that immunonutrition has the potential to help patients but its place must be more clearly defined before its widespread acceptance into clinical practice is based on sound scientific evidence.
Original languageEnglish
Pages (from-to)325-332
Number of pages8
JournalNutrición Hospitalaria
Volume19
Issue number6
Publication statusPublished - 2004

Fingerprint

Food
Multicenter Studies
Meta-Analysis
Clinical Trials

Keywords

  • Clinical Trials as Topic
  • Evidence-Based Medicine
  • Humans
  • Immunity
  • Nutritional Physiological Phenomena
  • Immunonutrition

Cite this

Heys, S. D., Schofield, A. C., & Wahle, K. W. J. (2004). Immunonutrition in clinical practice. Nutrición Hospitalaria, 19(6), 325-332.

Immunonutrition in clinical practice. / Heys, Steven Darryll; Schofield, Andrew Craig; Wahle, Klaus Wilfried Juergen.

In: Nutrición Hospitalaria, Vol. 19, No. 6, 2004, p. 325-332.

Research output: Contribution to journalArticle

Heys, SD, Schofield, AC & Wahle, KWJ 2004, 'Immunonutrition in clinical practice', Nutrición Hospitalaria, vol. 19, no. 6, pp. 325-332.
Heys SD, Schofield AC, Wahle KWJ. Immunonutrition in clinical practice. Nutrición Hospitalaria. 2004;19(6):325-332.
Heys, Steven Darryll ; Schofield, Andrew Craig ; Wahle, Klaus Wilfried Juergen. / Immunonutrition in clinical practice. In: Nutrición Hospitalaria. 2004 ; Vol. 19, No. 6. pp. 325-332.
@article{203a25feff49461cac35299256bbc33d,
title = "Immunonutrition in clinical practice",
abstract = "The clinical trials of immunonutrition that we have undertaken have often been small, single centre studies. They have often been of limited statistical power and have often included patients with a variety of underlying disease states and at different points in the disease process. Three meta-analysis and a consensus statement in conjunction with a systematic review, have been performed in an attempt to overcome many of these limitations and understand further the clinical place for immunonutrition. However, there are still many questions regarding the place of immunonutrition in clinical practice that we still do not understand or have definitive answers to. For example, do we really know what is the optimal combination of nutrients and in what quantities they should be provided? Do we understand any potential interactions that might occur between these nutrients? What is the effect of the patients nutritional state? When and for how long should immunonutrition provided? What is the impact of the patients' underlying disease process and how does this interact with the provision of immunonutrition? At the present time whilst there is some indication and evidence as to which patients might benefit most, and as to those who may not benefit or even suffer detrimental effects from immunonutrition, we still can not answer these questions with any definitive authority. It is essential now that we undertake large well designed, well controlled multicentre studies with adequate statistical power to answer these questions. The indications are that immunonutrition has the potential to help patients but its place must be more clearly defined before its widespread acceptance into clinical practice is based on sound scientific evidence.",
keywords = "Clinical Trials as Topic, Evidence-Based Medicine, Humans, Immunity, Nutritional Physiological Phenomena, Immunonutrition",
author = "Heys, {Steven Darryll} and Schofield, {Andrew Craig} and Wahle, {Klaus Wilfried Juergen}",
year = "2004",
language = "English",
volume = "19",
pages = "325--332",
journal = "Nutrici{\'o}n Hospitalaria",
issn = "0212-1611",
publisher = "Grupo Aula Medica S.A.",
number = "6",

}

TY - JOUR

T1 - Immunonutrition in clinical practice

AU - Heys, Steven Darryll

AU - Schofield, Andrew Craig

AU - Wahle, Klaus Wilfried Juergen

PY - 2004

Y1 - 2004

N2 - The clinical trials of immunonutrition that we have undertaken have often been small, single centre studies. They have often been of limited statistical power and have often included patients with a variety of underlying disease states and at different points in the disease process. Three meta-analysis and a consensus statement in conjunction with a systematic review, have been performed in an attempt to overcome many of these limitations and understand further the clinical place for immunonutrition. However, there are still many questions regarding the place of immunonutrition in clinical practice that we still do not understand or have definitive answers to. For example, do we really know what is the optimal combination of nutrients and in what quantities they should be provided? Do we understand any potential interactions that might occur between these nutrients? What is the effect of the patients nutritional state? When and for how long should immunonutrition provided? What is the impact of the patients' underlying disease process and how does this interact with the provision of immunonutrition? At the present time whilst there is some indication and evidence as to which patients might benefit most, and as to those who may not benefit or even suffer detrimental effects from immunonutrition, we still can not answer these questions with any definitive authority. It is essential now that we undertake large well designed, well controlled multicentre studies with adequate statistical power to answer these questions. The indications are that immunonutrition has the potential to help patients but its place must be more clearly defined before its widespread acceptance into clinical practice is based on sound scientific evidence.

AB - The clinical trials of immunonutrition that we have undertaken have often been small, single centre studies. They have often been of limited statistical power and have often included patients with a variety of underlying disease states and at different points in the disease process. Three meta-analysis and a consensus statement in conjunction with a systematic review, have been performed in an attempt to overcome many of these limitations and understand further the clinical place for immunonutrition. However, there are still many questions regarding the place of immunonutrition in clinical practice that we still do not understand or have definitive answers to. For example, do we really know what is the optimal combination of nutrients and in what quantities they should be provided? Do we understand any potential interactions that might occur between these nutrients? What is the effect of the patients nutritional state? When and for how long should immunonutrition provided? What is the impact of the patients' underlying disease process and how does this interact with the provision of immunonutrition? At the present time whilst there is some indication and evidence as to which patients might benefit most, and as to those who may not benefit or even suffer detrimental effects from immunonutrition, we still can not answer these questions with any definitive authority. It is essential now that we undertake large well designed, well controlled multicentre studies with adequate statistical power to answer these questions. The indications are that immunonutrition has the potential to help patients but its place must be more clearly defined before its widespread acceptance into clinical practice is based on sound scientific evidence.

KW - Clinical Trials as Topic

KW - Evidence-Based Medicine

KW - Humans

KW - Immunity

KW - Nutritional Physiological Phenomena

KW - Immunonutrition

M3 - Article

C2 - 15672647

VL - 19

SP - 325

EP - 332

JO - Nutrición Hospitalaria

JF - Nutrición Hospitalaria

SN - 0212-1611

IS - 6

ER -